| PPD Announces Effectiveness of Furiex Pharmaceuticals' Registration Statement on Form 10 (Business Wire) WILMINGTON, N.C.----PPD, Inc. announced today that, in connection with its proposed spin-off of Furiex Pharmaceuticals, Inc., the Securities and Exchange Commission has declared effective Furiex Pharmaceuticals' Registration Statement on Form 10. us.rd.yahoo.com |
Senate Acts to Block Doctors' Medicare Payment Cut Senate Democrats and Republicans agreed to postpone by six months scheduled cuts in Medicare payments to doctors. online.wsj.com |
Elan Holds Tight on Selling Drug Tech Unit The Burrill Report submits: By Michael FitzhughElan (ELN) says it intends to unload $500 million in debt and will delay spinning off its drug delivery technology unit for now in light of poor market conditions. The current market is “not conducive to an appropriate valuation” of Elan Drug Technologies, the company says, noting that it is pleased with the unit’s “strong performance” and the recent launch of Ampyra, a multiple sclerosis drug dispersed using Elan’s technology, with partner Acorda Therapeutics. Complete Story » seekingalpha.com |
Similar Companies Don't Always Have Similar Stocks Eddy Elfenbein submits: OK class, today’s lesson is on the pitfalls of similar stock performance. It’s tempting to think that all companies in a certain industry behave the same way. The reason why is that in the short term, they often do. Once you start following a sector closely, you’ll see that, say, all the major banks will go up or down together on a particular day. In fact, if bad news hits one company, then all of its competitors will behave similarly that day, albeit not as much. Oddly, one would think that bad news hitting a competitor would be a positive, but such is often not the case.Complete Story » seekingalpha.com |
Slim Hopes for Obesity Drugs to Gain Approval The Burrill Report submits: By Michael FitzhughThe U.S. Food and Drug Administration’s rejection of Arena’s (ARNA) experimental obesity drug lorcaserin now shifts public attention to two other contenders set to come before the agency for review. Investors looking to cash in on a largely untapped market opportunity are left with thinning expectations for success. Complete Story » seekingalpha.com |